1. Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:671-685.
3. Palacios S, Neyro JL, Fernandez de Cabo S, et al. Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women. Climacteric 2014;17:60-70.
4. Lee HM, Park SY, Lee SH, et al. Comparative analysis of clinical outcomes in patients with osteoporotic vertebral compression fractures (OVCFs): conservative treatment versus balloon kyphoplasty. Spine J 2012;12:998-1005.
7. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12S-17S. discussion 17S-19S.
8. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
9. Hubschle L, Borgström F, Olafsson G, et al. Real-life results of balloon kyphoplasty for vertebral compression fractures from the SWISSspine registry. Spine J 2014;14:2063-2077.
15. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-521.
16. Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992;13(Suppl 2):S27-S31.
19. Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 1999;9:508-515.
25. Lee YK, Nam HS, Chuang LH, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 2009;12:1187-1193.
26. Kim SH, Hwang JS, Kim TW, et al. Validity and reliability of the EQ-5D for cancer patients in Korea. Support Care Cancer 2012;20:3155-3160.
27. Räsänen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006;22:235-241.
29. Carreon LY, Bratcher KR, Das N, et al. Estimating EQ-5D values from the Oswestry Disability Index and numeric rating scales for back and leg pain. Spine (Phila Pa 1976) 2014;39:678-682.
30. Mueller B, Carreon LY, Glassman SD. Comparison of the EuroQOL-5D with the Oswestry Disability Index, back and leg pain scores in patients with degenerative lumbar spine pathology. Spine (Phila Pa 1976) 2013;38:757-761.
32. Lee SI. Validity and reliability evaluation for EQ-5D in Korea. Osong: Korea Centers for Disease Control and Prevention; 2011.
35. Huang C, Ross PD, Wasnich RD. Vertebral fractures and other predictors of back pain among older women. J Bone Miner Res 1996;11:1026-1032.
36. Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. Spine (Phila Pa 1976) 2000;25:3100-3103.
38. Kim SH, Oh YM, Jo MW. Health-related quality of life in chronic obstructive pulmonary disease patients in Korea. Health Qual Life Outcomes 2014;12:57
39. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996;18:185s-189s.
40. Kim DY, Lee SH, Lee HY, et al. Validation of the Korean version of the oswestry disability index. Spine (Phila Pa 1976) 2005;30:E123-E127.
41. Cockerill W, Ismail AA, Cooper C, et al. Does location of vertebral deformity within the spine influence back pain and disability? European Vertebral Osteoporosis Study (EVOS) Group. Ann Rheum Dis 2000;59:368-371.
42. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009;361:557-568.
44. Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet 2010;376:1085-1092.
45. Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 2009;373:1016-1024.
47. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016;374:254-262.
48. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
49. Chesnut CH, 3rd , Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
50. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
51. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
53. Madureira MM, Bonfá E, Takayama L, et al. A 12-month randomized controlled trial of balance training in elderly women with osteoporosis: improvement of quality of life. Maturitas 2010;66:206-211.